Pre-order Enquiry
Request Free Sample
Global Artificial Pancreas Device System (APDS) Market Size, Status and Forecast 2021-2027
SKU ID : QYR-17783330 | Publishing Date : 23-Mar-2021 | No. of pages : 95
The Artificial Pancreas Device System is a system of devices that closely mimics the glucose regulating function of a healthy pancreas.
Most Artificial Pancreas Device Systems consists of three types of devices already familiar to many people with diabetes: a continuous glucose monitoring system (CGM) and an insulin infusion pump. A blood glucose device (such as a glucose meter) is used to calibrate the CGM.
A computer-controlled algorithm connects the CGM and insulin infusion pump to allow continuous communication between the two devices. Sometimes an artificial pancreas device system is referred to as a "closed-loop" system, an "automated insulin delivery" system, or an "autonomous system for glycemic control."
An Artificial Pancreas Device System will not only monitors glucose levels in the body but also automatically adjusts the delivery of insulin to reduce high blood glucose levels (hyperglycemia) and minimize the incidence of low blood glucose (hypoglycemia) with little or no input from the patient.
The classification of artificial pancreas devices systems includes threshold suspended device systems and hybrid closed-loop APDS, and the proportion of artificial pancreas devices systems in 2017 is about 60%, and the proportion is in decreasing trend from 2013 to 2017.
Artificial pancreas devices systems are widely used in hospital and clinic. The most proportion of artificial pancreas devices systems is in hospital, and the proportion in 2017 is about 59%.
North America is the largest consumption place, with a consumption market share nearly 54% in 2017. Following North America, Europe is the second largest consumption place with the consumption market share of 35%.
Market competition is intense. Medtronic is the leader of the industry, and it holds key technologies and patents, with high-end customers; has been formed in the monopoly position in the industry.
Market Analysis and Insights: Global Artificial Pancreas Device System (APDS) Market
The global Artificial Pancreas Device System (APDS) market size is projected to reach US$ 160.2 million by 2027, from US$ 71 million in 2020, at a CAGR of 12.1% during 2021-2027.
With industry-standard accuracy in analysis and high data integrity, the report makes a brilliant attempt to unveil key opportunities available in the global Artificial Pancreas Device System (APDS) market to help players in achieving a strong market position. Buyers of the report can access verified and reliable market forecasts, including those for the overall size of the global Artificial Pancreas Device System (APDS) market in terms of revenue.
On the whole, the report proves to be an effective tool that players can use to gain a competitive edge over their competitors and ensure lasting success in the global Artificial Pancreas Device System (APDS) market. All of the findings, data, and information provided in the report are validated and revalidated with the help of trustworthy sources. The analysts who have authored the report took a unique and industry-best research and analysis approach for an in-depth study of the global Artificial Pancreas Device System (APDS) market.
Global Artificial Pancreas Device System (APDS) Scope and Market Size
Artificial Pancreas Device System (APDS) market is segmented by company, region (country), by Type, and by Application. Players, stakeholders, and other participants in the global Artificial Pancreas Device System (APDS) market will be able to gain the upper hand as they use the report as a powerful resource. The segmental analysis focuses on revenue and forecast by Type and by Application in terms of revenue and forecast for the period 2016-2027.
Segment by Type
Threshold Suspended Device Systems
Hybrid Closed-loop APDS
Other Systems
Segment by Application
Hospitals
Clinics
By Region
North America
U.S.
Canada
Europe
Germany
France
U.K.
Italy
Russia
Nordic
Rest of Europe
Asia-Pacific
China
Japan
South Korea
Southeast Asia
India
Australia
Rest of Asia
Latin America
Mexico
Brazil
Rest of Latin America
Middle East & Africa
Turkey
Saudi Arabia
UAE
Rest of MEA
By Company
Medtronic
Bigfoot Biomedical
Beta Bionics
Admetsys
Insulet
Tandem Diabetes Care
Defymed
Most Artificial Pancreas Device Systems consists of three types of devices already familiar to many people with diabetes: a continuous glucose monitoring system (CGM) and an insulin infusion pump. A blood glucose device (such as a glucose meter) is used to calibrate the CGM.
A computer-controlled algorithm connects the CGM and insulin infusion pump to allow continuous communication between the two devices. Sometimes an artificial pancreas device system is referred to as a "closed-loop" system, an "automated insulin delivery" system, or an "autonomous system for glycemic control."
An Artificial Pancreas Device System will not only monitors glucose levels in the body but also automatically adjusts the delivery of insulin to reduce high blood glucose levels (hyperglycemia) and minimize the incidence of low blood glucose (hypoglycemia) with little or no input from the patient.
The classification of artificial pancreas devices systems includes threshold suspended device systems and hybrid closed-loop APDS, and the proportion of artificial pancreas devices systems in 2017 is about 60%, and the proportion is in decreasing trend from 2013 to 2017.
Artificial pancreas devices systems are widely used in hospital and clinic. The most proportion of artificial pancreas devices systems is in hospital, and the proportion in 2017 is about 59%.
North America is the largest consumption place, with a consumption market share nearly 54% in 2017. Following North America, Europe is the second largest consumption place with the consumption market share of 35%.
Market competition is intense. Medtronic is the leader of the industry, and it holds key technologies and patents, with high-end customers; has been formed in the monopoly position in the industry.
Market Analysis and Insights: Global Artificial Pancreas Device System (APDS) Market
The global Artificial Pancreas Device System (APDS) market size is projected to reach US$ 160.2 million by 2027, from US$ 71 million in 2020, at a CAGR of 12.1% during 2021-2027.
With industry-standard accuracy in analysis and high data integrity, the report makes a brilliant attempt to unveil key opportunities available in the global Artificial Pancreas Device System (APDS) market to help players in achieving a strong market position. Buyers of the report can access verified and reliable market forecasts, including those for the overall size of the global Artificial Pancreas Device System (APDS) market in terms of revenue.
On the whole, the report proves to be an effective tool that players can use to gain a competitive edge over their competitors and ensure lasting success in the global Artificial Pancreas Device System (APDS) market. All of the findings, data, and information provided in the report are validated and revalidated with the help of trustworthy sources. The analysts who have authored the report took a unique and industry-best research and analysis approach for an in-depth study of the global Artificial Pancreas Device System (APDS) market.
Global Artificial Pancreas Device System (APDS) Scope and Market Size
Artificial Pancreas Device System (APDS) market is segmented by company, region (country), by Type, and by Application. Players, stakeholders, and other participants in the global Artificial Pancreas Device System (APDS) market will be able to gain the upper hand as they use the report as a powerful resource. The segmental analysis focuses on revenue and forecast by Type and by Application in terms of revenue and forecast for the period 2016-2027.
Segment by Type
Threshold Suspended Device Systems
Hybrid Closed-loop APDS
Other Systems
Segment by Application
Hospitals
Clinics
By Region
North America
U.S.
Canada
Europe
Germany
France
U.K.
Italy
Russia
Nordic
Rest of Europe
Asia-Pacific
China
Japan
South Korea
Southeast Asia
India
Australia
Rest of Asia
Latin America
Mexico
Brazil
Rest of Latin America
Middle East & Africa
Turkey
Saudi Arabia
UAE
Rest of MEA
By Company
Medtronic
Bigfoot Biomedical
Beta Bionics
Admetsys
Insulet
Tandem Diabetes Care
Defymed
Frequently Asked Questions
This market study covers the global and regional market with an in-depth analysis of the overall growth prospects in the market. Furthermore, it sheds light on the comprehensive competitive landscape of the global market. The report further offers a dashboard overview of leading companies encompassing their successful marketing strategies, market contribution, recent developments in both historic and present contexts.
- By product type
- By End User/Applications
- By Technology
- By Region
The report provides a detailed evaluation of the market by highlighting information on different aspects which include drivers, restraints, opportunities, and threats. This information can help stakeholders to make appropriate decisions before investing.
Request Sample
Request Discount
